| Abbott (23) |  |
| Amgen (10) | |
| Astra-merck (6) | |
| Bayer (41) | |
| Boehringer-ingelheim (1) | |
| Bristol-myers-squibb (5) | |
| Dupont-merck (14) | |
| Eli lilly (5) | |
| Genentech (5) | |
| Genzyme (5) | |
| Glaxosmithkline (26) | |
| Hoechst-marion-roussel (4) | |
| Pasteur-merieux (8) | |
| Pfizer (22) | |
| Pharmaceutical industry (36) | |
| Pharmaceutical laboratory (1) | |
| Pharmacyclics (1) | |
| Roche pharmaceuticals (16) | |
| Sanofi-aventis (6) | |
| Stallergenes (1) | |
| Whitehall laboratories (3) | |
and will be run by Arthur Levinson, chairman and ex-CEO of biotech company Genentech. Google gave exclusive access to Time magazine for a story on the new venture.
Arthur D. Levinson, Chairman and former CEO of Genentech and Chairman of Apple, will be Chief executive officer and a founding investor.
#Art Levinson will remain Chairman of Genentech and a director of Hoffmann-la roche, as well as Chairman of Apple.
#oeart s track record at Genentech has been exemplary, and we see an interesting potential for our companies to work together going forward.
Art Levinson, Chairman and former CEO of Genentech and Chairman of Apple, will be Chief executive officer. OK#so you re probably thinking wow!
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011